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Abstract
Background: Activated Protein C (ProC) is an anticoagulant plasma serine protease which also
plays an important role in controlling inflammation and cell proliferation. Several mutations of the
gene are associated with phenotypic functional deficiency of protein C, and with the risk of
developing venous thrombosis. Structure prediction and computational analysis of the mutants
have proven to be a valuable aid in understanding the molecular aspects of clinical thrombophilia.
Results: We have built a specialized relational database and a search tool for natural mutants of
protein C. It contains 195 entries that include 182 missense and 13 stop mutations. A menu driven
search engine allows the user to retrieve stored information for each variant, that include genetic
as well as structural data and a multiple alignment highlighting the substituted position. Molecular
models of variants can be visualized with interactive tools; PDB coordinates of the models are also
available for further analysis. Furthermore, an automatic modelling interface allows the user to
generate multiple alignments and 3D models of new variants.
Conclusion: ProCMD is an up-to-date interactive mutant database that integrates phenotypical
descriptions with functional and structural data obtained by computational approaches. It will be
useful in the research and clinical fields to help elucidate the chain of events leading from a
molecular defect to the related disease. It is available for academics at the URL http://
www.itb.cnr.it/procmd/.
Background
Activated protein C (APC) is a vitamin K-dependent serine
protease that plays a central role in the regulation of blood
coagulation. It is the key component of an anticoagulant
system that provides an essential mechanism in thrombo-
sis prevention and in inflammatory response control.
APC binds to its cofactor protein S, and the complex inac-
tivates the two cofactors involved in the clotting cascade,
factors Va and factor VIIIa, leading to the efficient inhibi-
tion of the coagulation process. Furthermore APC has
direct and indirect anti-inflammatory actions. It prevents
leukocyte rolling, tissue factor exposure and tumour
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mediated inflammatory actions and apoptosis of
endothelial cells [1]. The anti-thrombotic and anti-
inflammatory actions of APC have been therapeutically
exploited in severe sepsis [2].
Protein C, the zymogen of APC, is synthesized as a single
chain precursor containing an amino-terminal leader
sequence followed by a propeptide, which are cleaved
upon secretion. It circulates in plasma mostly as a two-
chain zymogen obtained by removal of the dipeptide
Lys198 and Arg199 that results in the formation of two
chains (light, 21 kDa and heavy, 41 kDa) linked by a
disulphide bridge between Cys183 and Cys320. The
zymogen is activated by thrombin through the proteolytic
cleavage of a 12 amino acid peptide (Asp200-Arg211) [3].
The activation occurs on the endothelium of blood vessels
by the thrombin-thrombomodulin complex [4] and this
process is enhanced by the endothelial cell protein C
receptor (EPCR) [5].
Protein C has a multi-domain structure: the light chain
contains a γ-carboxyglutamic acid (Gla)-rich membrane
binding domain and two epidermal growth factor (EGF)-
like modules, while the heavy chain has the form of a typ-
ical trypsin-like serine protease domain [3].
The structure of the Gla-domainless APC has been solved
by X-ray crystallography [6], while the structure of the Gla-
domain is available in the complex with endothelial pro-
tein C receptor [7]. Protein C shares homologies with
other vitamin K-dependent coagulation proteins as a
result of a common evolutionary pathway.
Mutations on the gene have been found in patients with
protein C deficiency (OMIM 176860), a disorder associ-
ated with development of purpura fulminans and severe
recurrent thrombotic events in the homozygous form
while, in the heterozygous form, it is responsible for an
increased risk of venous thromboembolism in early adult-
hood [8,9].
Phenotypically, two distinct types of protein C deficiency
are recognized: type I deficiency, the most common, is
characterized by a parallel reduction in protein C concen-
tration and function (measured in plasma by amidolytic
or anticoagulant methods); type II deficiency is identified
by normal or increased concentration and reduced func-
tion [10].
A large number of the mutations that contribute to the
protein C deficiency fall in the structurally solved
domains and thus are amenable to homology modelling
and computational analysis.
Structural models can be useful in the research and clini-
cal fields to elucidate how a mutation may interfere with
enzymatic activity, ligand binding and cofactor interac-
tion and relate the effect to patient phenotype.
In the last published database of mutations of the protein
C gene [10,11], 161 different mutations (corresponding
to 351 entries) are reported. Additional variants can be
obtained from other sources (Human Gene Mutation
Database [12,13] and the Swiss-Prot Variant Page [14,15].
However, to our knowledge, none of the available collec-
tions include data on the structural-functional interpreta-
tion of reported variants.
We describe here an updated, 3D-structure oriented data-
base of protein C that associates clinical and phenotypical
descriptions with functional and structural data obtained
by computational approaches. It includes the description
of 21 new variants that we have identified and analyzed in
a previous work [16][17]. The database is integrated with
an interactive search interface and with tools for structure
visualization and mutant modelling.
Construction and content
Dataset
We collected a total of 195 naturally occurring mutations
in the coding region of the protein C gene that include
182 missense and 13 stop mutations. Of these, a set of 21
variants were identified by our group through the screen-
ing of the protein C gene of 42 patients with a phenotypic
functional deficiency of protein C [17]. The remaining
portion of the dataset consists of missense and nonsense
variants already reported, obtained from 3 different
sources: the database of mutations of protein C gene
[10,11], the Human Gene Mutation Database [12,13] and
the Swiss-Prot Variant Page [14,15]. Additional variants,
not included in the above databases, were obtained from
literature. The entries were manually extracted and filtered
to avoid duplicates.
General information associated with each entry was
derived from literature sources. A multiple alignment
obtained with CLUSTALW [18] using a set of orthologous
and paralogous sequences was also associated with each
entry.
Variants with substitutions in the structurally solved
regions of the protein C, have been modelled starting
from X-ray coordinates (PDB entry 1AUT). Molecular
modelling of the 21 variants identified by our group, were
achieved by residue replacement using InsightII (Accelrys
INC., San Diego, Ca, USA). The lowest energy rotamer was
chosen as the starting side chain position, followed by
energy minimization calculation consisting of 500 steps
of steepest descent keeping the backbone fixed, followedPage 2 of 6
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A detailed computational analysis of these variants, such
as electrostatic potential calculations, was formerly carried
out and the results are also stored in the database.
All other variants were modelled using an automatic
approach based on an adapted Python script of Modeller
[19]. The script replaces the side chain of the mutated res-
idue in the PDB file (1AUT) and optimizes the conforma-
tion by energy minimization and molecular dynamics.
For each variant modelled, a set of 3D molecular represen-
tation were constructed using the programs PyMol
(PyMOL Molecular Graphics System, DeLano Scientific,
San Carlos, CA, USA) and MOLSCRIPT [20] to obtain
fixed images and VRML (Virtual Reality Modelling Lan-
guage) files. VRMLs can be viewed through a browser in a
dynamic, interactive way using a player like CORTONA2
[21].
Database and User Interface
The data are stored in a relational database managed by a
MySQL Database Management System [22]. The database
at the moment contains four tables: a "Mutations" table
with all the single point mutation entries, a "Variants"
table with clinical comments and, if available, literature
data concerning each mutant; and two other tables with
structural information about domains, chains, secondary
structures, molecular modelling results and structure-
function relationships.
We created a web based interface with the aim of helping
users search for specific information, to browse the entire
database or to visualize 2D and 3D images of the variants.
The web site is also a source of documentation about pro-
tein C, and a point of access to external resources and
databases related to protein C. This user interface has been
built with PHP language scripts [23] on an Apache Web
Server [24].
Entry description
All entries in the database are labeled by an unique iden-
tifier and may include the following fields:
- sequence position of the mutated residues numbered
according to:UniProtKB/Swiss-Prot entry P04070, Foster's
codon numbering [25] and the chymotrypsin numbering
used in PDB entry 1AUT when the substituted residue is
included in the X-ray structure of protein C;
- wild type and mutated residues;
- gene localization;
- clinical or laboratory phenotype data as obtained from
other database reports or from the literature;
- links to PUBMED database;
- cross-references to other databases reporting the muta-
tion.
- There is also a structural information section that assigns
the mutated residue to its specific chain, secondary struc-
ture and domain localization. A multiple alignment of
homologous sequences, a 3D gallery of structural images
and the PDB coordinates of the mutants are also present.
Results of computational analysis are collected in a 3D-
notes page that includes considerations on the physico-
chemical properties of the mutant residue compared to
the wild-type, (i.e. charge, hydrophobicity, solvent acces-
sibility), a list of hydrogen bonds and hydrophobic inter-
actions. Additional information resulting from further
computational studies, such as electrostatic potential cal-
culation, and the prediction of structural-functional
effects of the mutation are associated with some entries.
Utility and Discussion
The ProCMD database aims to provide a summary of the
sequence and structure information on variants with sub-
stitutions in the coding region of the protein C gene. The
database is interfaced with a fully interactive website,
through which the user can retrieve entries of interest, find
cross-references and visualize structural models with
interactive tools.
The home page of ProCMD web tool is shown in figure 1.
Images and animations represent some examples of struc-
tural details of protein C variants included in the data-
base. The menu on the left provides links to protein
description pages that summarize literature data on pro-
tein structure and function and clinical features. It also
provides a link to the database search interface and to
modelling tools as described below.
Data search and retrieval
A query page allows the user to retrieve entries by the posi-
tion in the sequence of a mutated residue, by amino acidic
substitution, and by domain localization. Results of the
query are listed in a table showing the amino acidic sub-
stitution and the sequence position for each entry, and
provide links to details pages summarizing all the associ-
ated data.
An example of the output is shown in figure 2. A distinc-
tive characteristics of ProCMD is that the mutation can be
evaluated in the context of the structural features of pro-
tein C: information on secondary structure, and domain
localization helps to predict whether a substitution can be
tolerated in the protein structure or is likely to affect pro-
tein stability. Sequence alignments of orthologous and
paralogous proteins are shown in the entry page with thePage 3 of 6
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help to evaluate the degree of conservation of the involved
residue in the context of structurally and/or functionally
relevant positions. Homology models of variants are
available as PDB files and can be visualized with molecu-
lar graphics tools. In addition, images of the modelled
mutant, mapping the substituted residue and the sur-
rounding region, have been created and can be seen either
in a static view or interactively through VRML. The coordi-
nates and images of the wild type are also available to
facilitate comparison. The VRML tool provides a ready
view of mutation location and of functional residues on
the 3D-structure and also displays interactions such as H-
bonds, salt- and disulphide-bridges.
Results of more detailed computational analysis and
interpretation of the effect of mutation, when available,
appear in a 3D-notes page with the corresponding images
(figure 3).
Taken together, all the data related to each variant are use-
ful to understand the relationship between the mutation
and phenotype and help to elucidate the role of specific
residues for protein function.
Analysis tools for new mutations
For other user-defined missense mutants, not present in
the database, the site provides tools for evaluating the res-
idue conservation and for the homology modelling of the
variant.
Selecting "Multiple alignments" from the home page (fig-
ure 1), the user can promptly visualize the residue of inter-
est in the homologous alignment to have hints on its
evolutionary conservation.
Molecular models can be obtained, if the residue falls in
the 3D-structure, by the same automatic procedure based
on the script of Modeller [19] used for entries preparation.
Models can be visualized and 3D coordinates can be
downloaded for further studies.
As the models are obtained in a completely automatic
way, the user is cautioned about the possibility of having
obtained non-accurate results. Careful inspection of the
outcome is therefore recommended.
Data submission
ProCMD features an online submission of mutation data.
New mutations regarding the coding region of the protein
C gene can be sent by filling out the fields on the online
submission form. A text mail will be automatically gener-
ated by the server and sent to the authors after submis-
sion. The database curators verify the submitted data and
will incorporate them after annotation according to the
database format.
Conclusion
This database provides a tool, complementary to other
mutant collections of protein C, that is especially devoted
to structural analysis and interpretation. A great effort has
been put into the production of 3D-images associated
with the molecular models and input files for interactive
viewers which visualize the models in 3D space. The avail-
ability of structural models can be useful in the research
and clinical fields both to elucidate how a mutation may
interfere with enzymatic activity, ligand binding and
cofactor interaction, and to relate the effect to patient phe-
notype. The present resource can be valuable to help pre-
dict the effect of a mutation, to clarify the role of specific
residues in protein function and hopefully to give hints
for the rational design of specific variants of protein C for
therapeutic use.
Availability and requirements
The database is maintained on the server of the Institute
of Biomedical Technology -National Research Council
(Segrate – MI, Italy) and is available at the following URL
http://www.itb.cnr.it/procmd
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Bank, APC: Activated Protein C, HGMD: Human Gene
The Home Page of the DatabaseFigure 1
The Home Page of the Database. The database menu is 
on the left-hand side of the web page. It contains links to gen-
eral information about gene, protein and clinical features of 
protein C deficiency, a link to the search in the database, 
links to mutations analysis tools, to authors correspondence, 
to a submission form for new mutations and to external web 
resources. Images are examples of structural details.Page 4 of 6
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Detailed view of an entry of the databaseFigur  2
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references. A great importance is given to the structural 
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A 3D-notes pageFigure 3
A 3D-notes page. The example refers to the variant 
G216D. Information on the physico-chemical properties of 
the mutant residue compared to wild-type (i.e. charge, 
hydrophobicity, solvent accessibility) is given, hydrogen 
bonds and hydrophobic interactions are listed. Additional 
data resulting from computational studies, such as electro-
static potential calculation, and the predicted effect of muta-
tion are also reported.Page 5 of 6
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